Revenue
2022
2023
2024
2025
LENZ Therapeutics, Inc. (LENZ)
Price$5.96Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | $0 | $15.0M | — | — |
| Gross profit | $18.7M | $0 | — | — | — | — |
| Gross margin | 97.81% | — | — | — | — | — |
| Research & development | $18.7M | $29.8M | $59.5M | $72.8M | $37.9M | $9.1M |
| Operating expenses | $110.2M | $58.6M | $72.4M | $105.6M | $60.4M | $13.5M |
| Operating income | −$91.1M | −$58.6M | −$72.4M | −$105.6M | −$60.4M | −$13.5M |
| Operating margin | −477.46% | — | — | −704.26% | — | — |
| EBITDA | −$90.9M | −$58.6M | −$72.4M | −$103.3M | −$59.7M | −$13.4M |
| EBITDA margin | −475.96% | — | — | −688.58% | — | — |
| Net income | −$82.1M | −$49.8M | −$70.0M | −$101.1M | −$70.8M | −$68.4M |
| Net profit margin | −430.25% | — | — | −673.68% | — | — |
| Basic EPSper basic share | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | -$29.93 |
| Diluted EPSper diluted share | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | -$29.93 |
Owners
Reported shareholders
≈14.42%of listed shares
Versant Vantage II GP-GP, LLC / Versant Vantage II GP, L.P. / Versant Venture Capital VII, L.P. / Versant Vantage II, L.P. / Versant Ventures VII GP, L.P. / Versant Ventures VI GP, L.P. / Versant Venture Capital VI, L.P. / Versant Ventures VI GP-GP, LLC / Versant Ventures VII GP-GP, LLC4.53M shares · Sep 30, 2025
View holders
| Holder | % owned |
|---|---|
Versant Vantage II GP-GP, LLC / Versant Vantage II GP, L.P. / Versant Venture Capital VII, L.P. / Versant Vantage II, L.P. / Versant Ventures VII GP, L.P. / Versant Ventures VI GP, L.P. / Versant Venture Capital VI, L.P. / Versant Ventures VI GP-GP, LLC / Versant Ventures VII GP-GP, LLC | ≈14.42%4.53M shares |
RA CAPITAL MANAGEMENT, L.P. | 13.30%4.18M shares |
Alpha Wave Global, LP | 11.50%3.61M shares |
FMR LLC | 11.33%3.56M shares |
Versant Venture Management, LLC | 8.46%2.66M shares |
BlackRock, Inc. | 7.30%2.29M shares |
Squarepoint Ops LLC | 5.56%1.75M shares |
Aberdeen Group plc | 4.93%1.55M shares |
MILLENNIUM MANAGEMENT LLC | 4.80%1.51M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.49%1.1M shares |
72 Investment Holdings, LLC | 3.24%1.02M shares |
Blue Owl Capital Holdings LP | 2.41%756.72K shares |
C WorldWide Group Holding A/S | 2.23%700K shares |
MCCOLLUM JAMES W | ≈2.01%631.1K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.80%564.66K shares |
Trexquant Investment LP | 1.58%497.53K shares |
MARSHALL WACE, LLP | 1.57%493.1K shares |
Qube Research & Technologies Ltd | 1.53%482.2K shares |
MORGAN STANLEY | 1.51%473K shares |
PRIMECAP MANAGEMENT CO/CA/ | 1.50%472.2K shares |
Percentages use 31.42M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 27, 2026Form 4 | George Jeffrey P.Director | BuyCommon Stock | 5.6K | $8.92 | $49.9K | 5.6K |
| Mar 27, 2026Form 4 | Schimmelpennink Evert B.President, CEO and Secretary | BuyCommon Stock | 28.1K | $8.95 | $251.4K | 77.3K |
| Mar 27, 2026Form 4 | Chevallard Daniel R.Chief Financial Officer | BuyCommon Stock | 7.5K | $8.57 | $64.3K | 12.9K |
| Nov 17, 2025Form 4 · 10b5-1 | Olsson ShawnChief Commercial Officer | SellCommon Stock | 5.8K | $26.37 | $152.6K | 4.7K |
| Nov 17, 2025Form 4 · 10b5-1 | Olsson ShawnChief Commercial Officer | SellCommon Stock | 4.2K | $25.74 | $108.4K | 10.5K |